Literature DB >> 3004325

Susceptibility of Campylobacter species to nalidixic acid, enoxacin, and other DNA gyrase inhibitors.

D E Taylor, L K Ng, H Lior.   

Abstract

Nalidixic acid-resistant mutants of Campylobacter jejuni and C. coli as well as "C. laridis" strains showed cross-resistance to another DNA gyrase subunit A inhibitor, enoxacin (MIC, 32 micrograms/ml), whereas C. fetus subsp. fetus, C. fetus subsp. venerealis, and "C. hyointestinalis" strains were all susceptible to enoxacin (MIC, less than or equal to 2 micrograms/ml). All Campylobacter species were resistant to novobiocin (MIC, 32 to 512 micrograms/ml), but most strains were susceptible to the other DNA gyrase subunit B inhibitors coumermycin A1 and clorobiocin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3004325      PMCID: PMC176366          DOI: 10.1128/AAC.28.5.708

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  NALIDIXIC ACID IN INFECTIONS OF URINARY TRACT. LABORATORY AND CLINICAL INVESTIGATIONS.

Authors:  A M BARLOW
Journal:  Br Med J       Date:  1963-11-23

2.  Differentiation of enteropathogenic Campylobacter.

Authors:  M B Skirrow; J Benjamin
Journal:  J Clin Pathol       Date:  1980-11       Impact factor: 3.411

3.  Antimicrobial susceptibility of Campylobacter jejuni with special reference to resistance patterns of Canadian isolates.

Authors:  M A Karmali; S De Grandis; P C Fleming
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

4.  Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids.

Authors:  S Inoue; T Ohue; J Yamagishi; S Nakamura; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

5.  Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth.

Authors:  D C Hooper; J S Wolfson; G L McHugh; M B Winters; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

6.  Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance.

Authors:  D Greenwood; M Osman; J Goodwin; W A Cowlishaw; R Slack
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

7.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

8.  Transmissible plasmids from Campylobacter jejuni.

Authors:  D E Taylor; S A De Grandis; M A Karmali; P C Fleming
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

9.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

10.  New, extended biotyping scheme for Campylobacter jejuni, Campylobacter coli, and "Campylobacter laridis".

Authors:  H Lior
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

View more
  19 in total

1.  Characterization of high-level quinolone resistance in Campylobacter jejuni.

Authors:  T D Gootz; B A Martin
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

Review 2.  Mechanisms of antibiotic resistance in Campylobacter species.

Authors:  D E Taylor; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

3.  Evaluation of the indoxyl acetate hydrolysis test for the differentiation of Campylobacters.

Authors:  D S Hodge; A Borczyk; L L Wat
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

4.  Cytotoxic and enterotoxic activities of Campylobacter jejuni are not specified by tetracycline resistance plasmids pMAK175 and pUA466.

Authors:  D E Taylor; W M Johnson; H Lior
Journal:  J Clin Microbiol       Date:  1987-01       Impact factor: 5.948

5.  Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents.

Authors:  T Lambert; F Mégraud; G Gerbaud; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

6.  Natural transformation in Campylobacter species.

Authors:  Y Wang; D E Taylor
Journal:  J Bacteriol       Date:  1990-02       Impact factor: 3.490

7.  Characterization of freshly isolated Campylobacter coli strains and suitability of selective media for their growth.

Authors:  L K Ng; D E Taylor; M E Stiles
Journal:  J Clin Microbiol       Date:  1988-03       Impact factor: 5.948

8.  Cloning and nucleotide sequence of the gyrA gene from Campylobacter fetus subsp. fetus ATCC 27374 and characterization of ciprofloxacin-resistant laboratory and clinical isolates.

Authors:  D E Taylor; A S Chau
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

9.  Development of resistance to quinolones in five patients with campylobacteriosis treated with norfloxacin or ciprofloxacin.

Authors:  H Adler-Mosca; J Lüthy-Hottenstein; G Martinetti Lucchini; A Burnens; M Altwegg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

10.  Emergence of fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli in subjects from Finland.

Authors:  H Rautelin; O V Renkonen; T U Kosunen
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.